{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-24-000012","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.948303+00:00","generated_at":"2026-06-02T09:55:05.645687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prothena Q1 net loss $72.2M ($1.34/sh); cash $548.7M; guides FY 2024 cash burn $208-225M","bullets":["Net loss $72.2M vs $46.9M YoY; revenue $0.1M vs $2.2M; R&D expenses $64.1M vs $44.8M.","Cash, equivalents & restricted cash $548.7M (no debt); expects ~$405M year-end 2024.","Phase 3 AFFIRM-AL (birtamimab) topline data expected 4Q24–2Q25; Phase 1 PRX012 update in 2024.","Bristol Myers Squibb initiated Phase 2 for BMS-986446 (tau antibody) in early Alzheimer’s.","Daniel G. Welch appointed independent director and Chair Designate; David Ford named Chief People Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-24-000012","json":"https://secwatch.observer/filing/0001559053-24-000012.json","markdown":"https://secwatch.observer/filing/0001559053-24-000012.md","text":"https://secwatch.observer/filing/0001559053-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000012/0001559053-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000012/prta-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:55:05.645687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12a8a1410d0744b64830d665688e93ca746d2252","claim":"PROTHENA CORP PUBLIC LTD CO reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Prothena Corporation plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000012/0001559053-24-000012-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}